Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company’s activities in the field of oncology.
The members of BioLineRx’s SAB include four renowned clinicians and translational scientists in oncology. These include: Professor Aaron Ciechanover, Ph.D., M.D., Head ofTumor and Vascular Biology Research Center, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology; Jorge Eduardo Cortes, M.D., Professor of Medicine and Deputy Chair, and Chief of the CML Section of the Department of Leukemia at The University of Texas, MD Anderson Cancer; Debasish Roychowdhury, M.D., President, Nirvan Consultants, LLC; and Prof. Yosef Yarden, Ph.D., the Harold and Zeda Goldenberg Chair of Molecular Cell Biology at the Weizmann Institute of Science, Israel.
Kinneret Savitsky, Ph.D., CEO of BioLineRx, remarked, “We welcome this prestigious group of scientists to our newly founded Oncology Scientific Advisory Board. The decision to form a SAB with a focus on oncology is a direct result of the Company’s strategic decision, over the last few years, to focus on the therapeutic fields of oncology and immunology. We believe that the knowledge and experience of this impressive group of key opinion leaders will be highly beneficial as we continue to develop BL-8040, our lead oncology and hematology platform, for multiple indications, and in the development and commercialization efforts of additional future oncology projects.” (Original Source)
Shares of Biolinerx closed yesterday at $1.62, up $0.14 or 9.46%. BLRX has a 1-year high of $3.28 and a 1-year low of $1.03. The stock’s 50-day moving average is $1.37 and its 200-day moving average is $1.72.
On the ratings front, Biolinerx has been the subject of a number of recent research reports. In a report issued on November 16, Maxim Group analyst Jason Kolbert assigned a Buy rating on BLRX. Separately, on November 5, Roth Capital’s Joseph Pantginis maintained a Buy rating on the stock and has a price target of $7.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Joseph Pantginis have a total average return of -11.6% and -1.6% respectively. Kolbert has a success rate of 32.2% and is ranked #3634 out of 3642 analysts, while Pantginis has a success rate of 40.0% and is ranked #3199.
Bioline Rx Ltd is a clinical stage biopharmaceutical development company engaged in identifying, in-licensing & developing therapeutic compounds.